Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (1401)	3/29/2000 8:47:00 PM
From: Lighthouse	Read Replies (1) \| Respond to of 3202

So the Two Headed God belches in our face: Pulled from CBS Marketwatch Janus to sell Incyte stake Janus Capital Corp. is planning to sell its stake in falling star Incyte Pharmaceuticals Inc., according to an SEC filing. The S-3 form indicated that Denver-based Janus seeks to sell 2 million shares held by seven of its mutual funds. Those shares, which represent a 6.3 percent stake in Incyte, are currently valued at $165 million. Incyte's stock closed down 20 13/16 at 82 1/2 ahead of the release of the filing. Palo Alto, Calif.-based Incyte (INCY: news, msgs), which creates information-based databases for pharmaceutical and biotechnology companies in drug discovery and development, has seen its stock price tumble by $198 over the past month. The company plans to change its name to Incyte Genomics later this year.